Join Growin Stock Community!

Exicure, inc.XCUR.US Overview

US StockHealthcare
(No presentation for XCUR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

XCUR AI Insights

XCUR Overall Performance

XCUR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

XCUR Recent Performance

1.34%

Exicure, inc.

0.05%

Avg of Sector

-0.31%

S&P500

XCUR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

XCUR Key Information

XCUR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

XCUR Profile

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Price of XCUR

XCUR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

XCUR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
74.42
PB Ratio
3.41
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1940.20%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.45
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
74.42
PB Ratio
3.41
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1940.20%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is XCUR's latest earnings report released?

    The most recent financial report for Exicure, inc. (XCUR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating XCUR's short-term business performance and financial health. For the latest updates on XCUR's earnings releases, visit this page regularly.

  • How much cash does XCUR have?

    At the end of the period, Exicure, inc. (XCUR) held Total Cash and Cash Equivalents of 4.44M, accounting for 0.29 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is XCUR's EPS continuing to grow?

    According to the past four quarterly reports, Exicure, inc. (XCUR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.39. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of XCUR?

    Exicure, inc. (XCUR)'s Free Cash Flow (FCF) for the period is -3.42M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 661.69% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.